Rice University

Dr. Omid Veiseh, Ph.D. is a professor of Bioengineering at Rice University where he leads a research program aimed at engineering next generation treatments for a wide range of human diseases by leveraging the latest techniques in synthetic biology, immunoengineering, and materials science to develop innovative cell-based platforms for real-time production of biologics. He is also a serial entrepreneur who has co-founded Sigilon Therapeutics (Nasdaq: SGTX), Avenge Bio, Pana Bio, and Curada Bio. These companies collectively have attracted ~ $500M in private and public investment capital.